The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 3, open-label, randomized study of rinatabart sesutecan (Rina-S) vs investigator’s choice (IC) of chemotherapy in patients with platinum-resistant ovarian cancer (PROC).
 
Angeles Secord
Leadership - GOG Foundation; NRG Oncology (Inst)
Stock and Other Ownership Interests - Amgen; Johnson & Johnson/Janssen
Consulting or Advisory Role - Abbvie
Research Funding - Abbvie (Inst); Aravive (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Eisai (Inst); Ellipses Pharma (Inst); Genentech (Inst); GlaxoSmithKline (Inst); I-Mab (Inst); Immunogen (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Mersana (Inst); OncoQuest Pharmaceuticals (Inst); Seagen (Inst); VBL Therapeutics (Inst); Zentalis (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate Author Royalty
(OPTIONAL) Uncompensated Relationships - Aravive; GOG Foundation; OncoQuest Pharmaceuticals; Roche/Genentech/Foundation Medicine; VBL Therapeutics
 
Elizabeth Lee
Honoraria - AADi
Consulting or Advisory Role - AADi; Genmab; OnCusp Therapeutics
Research Funding - AADi (Inst); Genmab (Inst); KSQ Therapeutics (Inst); Merck (Inst); OnCusp Therapeutics (Inst); ProfoundBio (Inst); Repare Therapeutics (Inst); Seagen (Inst)
 
Michael Sundborg
No Relationships to Disclose
 
Destin Black
Stock and Other Ownership Interests - Trials365
Honoraria - GOG Partners
Consulting or Advisory Role - Intuitive Surgical; Merck; Novita Pharmaceuticals
Research Funding - Acrivon Therapeutics (Inst); AOA Diagnostics (Inst); GEICO (Inst); GlaxoSmithKline (Inst); GOG Partners (Inst); Karyopharm Therapeutics (Inst); KLUS Pharma (Inst); Merck (Inst); OncoC4 (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - Momentis surgical
 
David Starks
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Lilly; Faeth Therapeutics; Verastem
 
Edwin Alvarez
Consulting or Advisory Role - Eisai; EMD Serono; GlaxoSmithKline; Immunogen; OncoSec
Research Funding - Aravive (Inst); Arsenal Biosciences, Inc (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Corcept Therapeutics (Inst); Genentech (Inst); Immunogen (Inst); Merck (Inst); Sumitomo Pharma Oncology (Inst); Tesaro/GSK (Inst); VBL Therapeutics (Inst)
 
David Spigel
Leadership - ASCO (Inst)
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Circle Pharma (Inst); Daiichi Sankyo (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Jazz Pharmaceuticals (Inst); Lyell Immunopharma (Inst); MedImmune (Inst); ModeX Therapeutics (Inst); Novartis (Inst); Novocure (Inst)
Research Funding - Abbvie (Inst); Agios (Inst); Amgen (Inst); Anheart Therapeutics (Inst); Apollomics (Inst); Arcus Biosciences (Inst); Arrys Therapeutics (Inst); Ascendis Pharma (Inst); Asher Biotherapeutics (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BioNTech (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Chugai Pharma (Inst); cyteir (Inst); Daiichi Sankyo (Inst); Denovo Biopharma (Inst); Eisai (Inst); Elevation Oncology (Inst); Ellipses Pharma (Inst); EMD Serono (Inst); Endeavor BioMedicines (Inst); Erasca, Inc (Inst); Faeth Therapeutics (Inst); Foundation Bio (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); GRAIL (Inst); Hutchison MediPharma (Inst); Incyte (Inst); Ipsen (Inst); Janssen Oncology (Inst); Janux Therapeutics (Inst); Jazz Pharmaceuticals (Inst); Kronos Bio (Inst); Lilly (Inst); Loxo (Inst); Lyell Immunopharma (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Millennium (Inst); Moderna Therapeutics (Inst); Molecular Templates (Inst); Monte Rosa Therapeutics (Inst); Nektar (Inst); Novartis (Inst); Novocure (Inst); Oncologie (Inst); Peloton Therapeutics (Inst); Phanes Therapeutics (Inst); PTC Therapeutics (Inst); PureTech (Inst); Razor Genomics (Inst); Repare Therapeutics (Inst); Rgenix (Inst); Seagen (Inst); Shenzhen Chipscreen Biosciences (Inst); Stemline Therapeutics (Inst); Strata Oncology (Inst); Synthekine (Inst); Taiho Oncology (Inst); Takeda (Inst); Tango Therapeutics (Inst); Tango Therapeutics (Inst); Tarveda Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst); Verastem (Inst); Zai Lab (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Genentech; Novartis
 
Noelle Cloven
Consulting or Advisory Role - Abbvie; Genmab; GlaxoSmithKline; Toray Industries
 
Lynne Knowles
No Relationships to Disclose
 
Anton Melnyk
No Relationships to Disclose
 
William Winter
No Relationships to Disclose
 
Michael McCollum
Employment - Virginia Oncology Associates
Research Funding - Genentech (Inst); GlaxoSmithKline (Inst); Pfizer (Inst); Seagen (Inst)
 
Ibrahima Soumaoro
Employment - Genmab
Stock and Other Ownership Interests - Bristol-Myers Squibb; Genmab
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genmab
 
Yan Liu
Employment - Genmab
 
Christian Marth
Honoraria - AstraZeneca; Eisai; GlaxoSmithKline; MSD
Consulting or Advisory Role - Abbvie; BeiGene; BioNTech; Eisai; Genmab; GlaxoSmithKline; MSD; Seagen
 
GOG-3107 Investigators; ENGOT-OV86 Investigators
No Relationships to Disclose